Ovadia Eli - ICL Israel External Director
| ICL Stock | ILA 1,718 12.00 0.70% |
Director
Mr. Ovadia Eli serves as Director at ICLIsrael Chemicals Ltd. since August 16, 2011. His work experience includes the following roles Chairman of the Board of Oil Refineries Ltd., Chairman of the Board of Israel Airports Authority, Israel Military Industry, Haifa Basic Oils Ltd. and I.C.P.I., Director at Israel Salt Industries Ltd., Shaarey Ribit Ltd., Zim Integrated Shipping Services Ltd., OPC Rotem Ltd. and at Adriel Israel Properties Ltd. He holds a Bachelors degree in Educational Administration and Supervision and Biblical Studies from Haifa University. He is also a graduate of the Lifshitz Teachers Academy, Jerusalem. since 2011.
| Age | 74 |
| Tenure | 13 years |
| Phone | (972) 3 684 4427 |
| Web | www.icl-group.com |
ICL Israel Management Efficiency
The company has return on total asset (ROA) of 0.1916 % which means that it generated a profit of $0.1916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4322 %, meaning that it generated $0.4322 on every $100 dollars invested by stockholders. ICL Israel's management efficiency ratios could be used to measure how well ICL Israel manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Moshe Koren | Bank Hapoalim | 81 | |
| Rina Baum | Elbit Systems | 73 | |
| JeanMichel Halfon | Teva Pharmaceutical Industries | 67 | |
| Rosemary Crane | Teva Pharmaceutical Industries | 59 | |
| Ruben Krupik | Bank Hapoalim | 67 | |
| Roberto Mignone | Teva Pharmaceutical Industries | 47 | |
| Nechemia Peres | Teva Pharmaceutical Industries | 60 | |
| Perry Nisen | Teva Pharmaceutical Industries | 63 | |
| Dov Ninveh | Elbit Systems | 71 | |
| Ehood Nisan | Elbit Systems | 51 | |
| Ronit Rokach | Bank Hapoalim | 61 | |
| Yehoshua Gleitman | Elbit Systems | 69 | |
| Asaf Azulay | Bank Hapoalim | 35 | |
| Noam Hanegbi | Bank Hapoalim | 61 | |
| Gerald Lieberman | Teva Pharmaceutical Industries | 72 | |
| Dalya Lev | Bank Hapoalim | 71 | |
| Yoram BenZeev | Elbit Systems | 74 | |
| Richard Kaplan | Bank Hapoalim | 63 | |
| Yuli Tamir | Elbit Systems | 65 | |
Management Performance
| Return On Equity | 0.43 | |||
| Return On Asset | 0.19 |
ICL Israel Chemicals Leadership Team
Elected by the shareholders, the ICL Israel's board of directors comprises two types of representatives: ICL Israel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ICL. The board's role is to monitor ICL Israel's management team and ensure that shareholders' interests are well served. ICL Israel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ICL Israel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Raviv Zoller, Chief Executive Officer | ||
| Nitzan Moshe, Executive Vice President - Global Operations | ||
| Tzipi OzerArmon, Independent Director | ||
| Lilach GevaHarel, Senior Vice President and Global General Counsel | ||
| Avisar Paz, Director | ||
| Yoav Doppelt, Executive Chairman of the Board | ||
| Ilana Fahima, Executive Vice President ICL Global Human Resources | ||
| Ido Lilian, Executive Vice President-Global Procurement | ||
| Reem Aminoach, Independent Director | ||
| Ruth Ralbag, External Independent Director | ||
| Noam Goldstein, President - Potash Division | ||
| Anantha Desikan, Executive Vice President Chief Innovation & Technology Officer | ||
| Maya Grinfeld, VP Communications | ||
| Aviram Lahav, Chief Officer | ||
| Aya Landman, Company VP | ||
| Ofer Lifshitz, President, ICL Phosphate Solutions Division | ||
| Lior Reitblatt, Independent Director | ||
| Nadav Kaplan, Independent Director | ||
| Kobi Altman, CFO, Executive Vice President | ||
| Anat TalKtalav, President ICL Industrial Products Division | ||
| Eli Amon, Executive Vice President ICL Innovative Ag Solutions Division | ||
| Aviad Kaufman, Director | ||
| Miri Mishor, Senior Vice President - ICL Global Information Technology | ||
| Ovadia Eli, External Director | ||
| Amir Meshulam, Senior Vice President Global Internal Auditor | ||
| Advocate GevaHarel, Exec Counsel | ||
| Elad Aharonson, Pres Solutions | ||
| Sagi Kabla, Director |
ICL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ICL Israel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.43 | |||
| Return On Asset | 0.19 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.34 % | |||
| Current Valuation | 43.75 B | |||
| Shares Outstanding | 1.29 B | |||
| Shares Owned By Insiders | 44.90 % | |||
| Shares Owned By Institutions | 25.12 % | |||
| Price To Book | 2.00 X | |||
| Price To Sales | 3.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ICL Israel Chemicals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for ICL Stock analysis
When running ICL Israel's price analysis, check to measure ICL Israel's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ICL Israel is operating at the current time. Most of ICL Israel's value examination focuses on studying past and present price action to predict the probability of ICL Israel's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ICL Israel's price. Additionally, you may evaluate how the addition of ICL Israel to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |